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Abstract
Background
A community based drug resistant tuberculosis (DR-TB) program has been incrementally
implemented in Khayelitsha, a high HIV and TB burden community in South Africa. We in-
vestigated loss from treatment (LFT), and post treatment outcomes of DR-TB patients in
this setting.
Methodology
LFT, defined as interruption of treatment for2 consecutive months was assessed among
patients initiating DR-TB treatment for the first time between January 2009 and July 2011.
Patients were traced through routine data sources to identify those who subsequently re-
started treatment and those who died. Additional information on patient status and survival
after LTF was obtained from community DR-TB counselors and from the national death reg-
istry. Post treatment outcomes were observed until July 2013.
Results
Among 452 patients initiating treatment for the first time within the given period, 30% (136)
were LFT, with 67% retention at 18 months. Treatment was restarted in 27 (20%) patients,
with additional resistance recorded in 2/25 (8%), excluding two with presumed DR-TB.
Overall, 34 (25%) patients died, including 11 who restarted treatment. Males and those in
the age category 15-25 years had a greater hazard of LFT; HR 1.93 (95% CI 1.35-2.75),
and 2.43 (95% CI 1.52-3.88) respectively. Older age (>35 years) was associated with a
greater hazard of death; HR 3.74 (1.13- 12.37) post treatment. Overall two-year survival
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was 62%. It was lower (45%) in older patients, and was 92% among those who received
>12 months treatment.
Conclusion
LFT was high, occurred throughout the treatment period and was particularly high among
males and those aged 15-25 years. Overall long term survival was poor. High rates of LFT
should however not preclude scale up of community based care given its impact in increas-
ing access to treatment. Further research is needed to support retention of DR-TB patients
on treatment, even within community based treatment programs.
Introduction
Multidrug resistant tuberculosis [(MDR-TB), defined asMycobacterium tuberculosis (M.tb)
isolates that are resistant to at least both isoniazid and rifampicin] [1], continues to increase in
many TB endemic settings [2–5]. Treatment success rates (cure or treatment completion) re-
main poor with 48% treatment success globally and 28% of patients reported as lost to follow
up or having no outcome, in 2012 and 2013 [2, 3]. Access to treatment for MDR-TB also re-
mains low with an estimated 28% case detection rate globally, and less than 20% of all estimat-
ed cases reported to be on treatment in 2012 [3]. A viable model for increasing MDR-TB case
detection and scaling up access to care is community-based MDR-TB care which has also been
successfully demonstrated in high HIV settings [3, 6–10]. Reported patient outcomes from
community based programs, although limited, have to date been similar to those from hospital
based programs [11].
In Khayelitsha, a high TB and HIV burden townshipin South Africa, a community-based
drug resistant TB [(DR-TB), defined as any rifampicin resistance] program, implemented from
2007 has substantially increased case detection, treatment initiation rates, and reduced the time
to treatment initiation [8]. We report on patients who were lost from treatment (LFT), defined
in our study as those who interrupted treatment for two or more consecutive months. Our ob-
jectives were to investigate LFT, and post treatment outcomes (return to treatment and surviv-
al) among DR-TB patients in this setting.
Methods
Setting
The patients analyzed were treated in the Khayelitsha decentralized community-based DR-TB
program, which is a partnership between the City of Cape Town, the Western Cape Provincial
government and Médecins sans Frontières (MSF) [12]. Khayelitsha sub-district is situated
40 km outside Cape Town, in South Africa. The population is estimated at 400 000, 55% of
whom live in informal dwellings [13]. 62% of residents 15–64 years were employed in 2011
[13]. The sub-district is served by 10 Primary Health Care (PHC) clinics and one district hospi-
tal. A 2008 survey estimated the DR-TB notification rate at 51/100,000/year [14]. In 2009, the
TB notification rate was estimated at 1,500 per 100,000 people per year, with antenatal HIV
prevalence estimated at 30% [12].
The Khayelitsha DR-TB program implemented from late 2007 has previously been de-
scribed in detail [8, 12]. In summary an existing TB program at primary care level was en-
hanced to support care for DR-TB patients by adding the following elements; i) training of
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healthcare workers (HCWs)(nurses, doctors, counselors, social workers) in managing patients
with suspected and confirmed DR-TB, (MSF has a dedicated Medical officer who assists
HCWs in managing patients with DR-TB, ii) individualized DR-TB counseling for all newly di-
agnosed patients, iii) assisting patients to access social assistance iv) enhanced programme su-
pervision and evaluation, v) strengthening and supporting TB infection control mechanisms in
health care facilities, vi) establishing a locally based sub-acute in-patient facility for patients to
receive support (when needed) while remaining close to their families, vii) specialist DR-TB
paediatric outreach services, viii) audiometry screening for early detection of hearing loss
among DR-TB patients [12], since aminoglycosides, key drugs in the treatment regimens can
cause hearing impairment and loss [15, 16].
DR-TB diagnosis and treatment
Drug susceptibility testing (DST) which was initially only available for TB cases considered at
high risk of DR-TB, (defined as patients previously treated for TB, those not responding to
first-line TB treatment, close contacts of patients with DR-TB, healthcare workers, mine work-
ers and those with a prison history), was expanded to all individuals with suspected TB with
the introduction of Xpert MTB/Rif [16, 17] from late 2011. Before the introduction of Xpert
MTB/Rif, DST for rifampicin and isoniazid was undertaken using a Line-Probe Assay (LPA,
Hain Lifesciences, Nehren, Germany) conducted on positiveM.tb positive cultures [18]. Sec-
ond line (resistance to a flouroquinolone and/or a second line injectable agent) DST was con-
ducted on solid media. Since late 2011, all Xpert MTB/Rif results are confirmed by LPA, with
second line DST conducted on solid media.
Treatment regimens used in the programme are generally in line with the World Health Or-
ganization (WHO), South African DR-TB treatment guidelines [15, 16], and are tailored ac-
cording to second-line DST results, with further adjustment when treatment appears to be
failing. The standard treatment regime includes kanamycin, ethambutol, ethionamide,
pyrazinamide, terizidone, moxifloxacin [8, 12]. Additional drugs are capreomycin, para-
aminosalicylic acid (PAS), high-dose isoniazid (INH), clofazimine and linezolid [8, 12]. Treat-
ment for MDR-TB consists of a 6 month intensive phase with 5 drugs that include an injectable
agent given for minimum of 6 months, followed by an 18 month continuation phase on oral
agents [16]. Culture conversion is defined as two consecutive negative cultures, taken at least
30 days apart [16]. Treatment is given for at least 18 months after culture conversion [16].
Treatment outcome definitions followWHO and the South African DR-TB treatment guide-
lines [15, 16].
Population and data collection
This was a retrospective analysis of routinely collected DR-TB program data. Patients normally
resident in Khayelitsha who were newly diagnosed and treated for DR-TB between January
2009 and July 2011 were eligible for inclusion. Patients who were transferred out during treat-
ment were excluded. Survival after LFT was determined passively by surveillance of DR-TB
clinic registers to identify patients who restarted treatment, and by conducting regular cross
linkage of civil registration numbers with the national death registry to determine deaths and
dates of death where registration numbers were available. For those without civil registration
numbers, information was obtained from DR-TB counselors who are highly active in local clin-
ics and in the community, and become aware of mortality among DR-TB patients, patients
who stop taking DR-TB treatment but continue attending local clinics for other conditions,
and those who move out of the area.
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Ethics approval for evaluation of the Khayelitsha DR-TB program was obtained from the
University of Cape Town Research Ethics Committee (Ref 540/2010).
Definition of lost from treatment (LFT), and lost to follow up (LTFU)
In the 2013 WHO revised TB definitions and reporting framework [1], patients who do not
start treatment or whose treatment is interrupted for two or more consecutive months (previ-
ously classified as defaulters) are classified as lost to follow up. For this analysis, we defined pa-
tients who interrupted treatment for two or more consecutive months as lost from treatment
(LFT), and those for whom we had no further information regarding treatment and/or mortali-
ty beyond the last known date of treatment as lost to follow up (LTFU). This is based on the re-
ality that many patients stop DR-TB treatment but may remain in care for other conditions.
Data analysis
The data were analysed using Stata version 12.0 (Stata Corp, College Station, TX, USA). Medi-
ans were used to summarize non-normally distributed continuous variables, and these were
compared using the Mann–Whitney test. The χ2 test was used to compare proportions. Patient
status (return to treatment and survival) post LFT was assessed until July 2013. Univariate and
multivariate cox regression was used to investigate factors associated with duration of
Table 1. Demographic characteristics of patients who started treatment between January 2009 and
July 2011 who had treatment outcomes by July 2013 (N = 452).
Characteristic n (%)
Age at diagnosis (years) 32 (IQR 24.4–38.4)
Gender: Female 230 (51)
HIV status
Negative 135 (30)
Positive 307 (68)
Unknown 10 (2)
Treatment initiation site
PHC Clinic 314 (69)
Sub-acute facility 58 (13)
Hospital 73 (16)
Other 7 (2)
Counselling sessions
Completed 287 (63)
Not completed 165
>40 DR-TB patients at the clinic (number of clinics)
Yes 4 (40)
No 6
Resistance pattern
Rifampicin mono resistance 90 (20)
Presumed DR-TB 32 (7)
MDR no 2ndline resistance 238 (53)
MDR plus 2ndline resistance 58 (13)
MDR 2ndline resistance unknown 34 (8)
PHC-Primary Health Care
MDR- multidrug resistance
doi:10.1371/journal.pone.0118919.t001
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treatment before LFT (this analysis excluded patients who died without being LFT), and with
time to mortality from date of LFT. The factors tested were, age at the time of DR-TB diagnosis,
gender, HIV status, resistance pattern, place of treatment initiation (primary care clinic, sub-
acute facility, or hospital), completion of all recommended counseling sessions and culture
conversion status at four months of treatment, for duration of treatment before LFT. For sur-
vival post treatment (calculated from the date of LFT, which was defined as the last treatment
date), we assessed the duration of treatment before LFT, age at the time of DR-TB diagnosis,
gender, culture conversion status at LFT, and resistance pattern. Factors that were statistically
significant (p< 0.05) on univariate analysis were included in multivariate analyses. A sensitivity
(multivariate) analysis including selected factors with p< 0.1 in univariate analysis was also
conducted. Life Table analyses were used to calculate patient retention on treatment over time
and survival post treatment. The log rank test as used to compare survival proportions.
Results
Patient demographics
452 patients who started DR-TB treatment for the first time between January 2009 and July
2011 were included. Among these 48% were successfully treated (160 cured and 55 completed
treatment), 30% (136) were LFT, 5% (22) were classified as failure of treatment and 17% (79)
died during treatment. The median age at diagnosis was 32 years, with similar proportions of
males and females initiating treatment (49% and 51% respectively), Table 1. Approximately
two thirds of the patients were HIV infected. The majority (69%) of patients initiated treatment
at their primary care clinic. Second line DST results were available for 368 patients (81%), and
among these 20 (4.4%) had XDR-TB (defined as resistance to a flouroquinolone and at least
one second-line injectable agent (kanamycin or capreomycin in our setting), in addition to
multidrug resistance [1], and 38 (8.4%) pre- XDR-TB (defined as isolates multidrug resistance
and resistance to either a flouroquinolone or an injectable agent, but not both).
LFT over time and factors associated with LFT
Seventy-nine patients died during treatment (without being LFT), and were excluded from this
analysis. Median treatment duration before LFT was 7.1 months (IQR 3.6–12.3). Eight percent
of patients (37/452) were LFT in the first 3 months of treatment, with 73% and 67% retention
at 12 and 18 months of treatment respectively, Fig. 1. In univariate analysis, patients aged
15–25 years, and males were more likely to be LFT, Table 2. These factors remained significant
in multivariate analysis, with those aged 25–35 years also having a significantly increased haz-
ard of LFT [HR 1.57 (95%CI 1.02–2.42)]. On inclusion of culture conversion at four months in
multivariate analysis, the findings remained unchanged with males and those aged 15–25 years
significantly more likely to be LFT, Table 2.
Return to treatment and survival post LFT
Fig. 2 shows the status of patients who were LFT at the end of our period of observation. No ad-
ditional information (beyond the last day of treatment), was available for 51 of the 136 patients,
after initial recording of LFT. The median period of observation for the remaining 85 patients
was 25 months (IQR 10–37 months). Thirty-five patients [35/136 (26%)] were reported to be
alive at the end of observation. Twenty-seven (27/136 (20%)), were known to have restarted
treatment during this period with the median time to restarting treatment at 6 months (IQR
4.7–13.8). Five (19%) of these 27 patients were then successfully treated, 8 (30%) died while on
treatment, 6 (22%) were then LTFU and a further 6 (22%) were LFT again (median duration of
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Fig 1. Retention on treatment: Patients remaining on treatment over the course of treatment (n = 393).
doi:10.1371/journal.pone.0118919.g001
Table 2. Association of factors with time to loss from DR-TB treatment—2009–2013 (n = 373*).
Variable Univariate analysis Multivariate analysis Multivariate analysis^
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age
0–15 years 0.94 (0.45–1.95) 0.12 1.02 (0.49–2.11) 0.97 1.07 (0.25–4.57) 0.93
>15–25 years 2.20 (1.38–3.50) # 0.001# 2.43 (1.52–3.88) # 0.001# 2.48 (1.37–4.47) 0.003#
>25–35 years 1.40 (0.92–2.14) 0.87 1.57 (1.02–2.42) # 0.04# 1.66 (0.97–2.86 0.07
>35 years Ref
Gender: Male 1.79 (1.26–2.53) # 0.001# 1.93 (1.35–2.75) # <0.001# 2.08 (1.31–3.28) 0.002#
HIV positive 0.98 (0.56–1.15) 0.24
Resistance pattern
Rifampicin mono resistance ref
MDR no 2ndline resistance 0.96 (0.64–1.45 0.85
MDR plus 2ndline resistance 0.71 (0.34–1.50) 0.37
MDR 2ndline resistance unknown 0.71 (0.33–1.54) 0.38
Presumed DR-TB 0.59 (0.25–1.42) 0.24
Treatment initiation site
PHC Clinic ref
Hospital 0.69 (0.39–1.22) 0.21
Sub-acute facility 0.86 (0.49–1.50) 0.60
Counselling sessions completed 0.83 (0.55–1.26) 0.94
Culture conversion at 4 months 2.07 (0.90–4.77) 0.09 2.14 (0.93–4.94) 0.07
* 79 patients who died while on treatment were excluded from this analysis
#statistically signiﬁcant
^ Sensitivity analysis-Multivariate analysis including Culture conversion status at 4 months of treatment
doi:10.1371/journal.pone.0118919.t002
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treatment 7.3 months (IQR 2.2–13.8)). The median age of the six patients who repeatedly dis-
continued treatment was 27 years (IQR 22.9–33.7); four were female and three were HIV
positive. Four of the total 34 patients (12%) known to have died had second line resistance
(1 pre-XDR-TB and 3 XDR-TB). Patients who died without returning to treatment were signif-
icantly older than those who returned and those reported to be alive (p = 0.001) at the end of
the observation period. Resistance profiles for 25 of the 27 patients who returned to treatment
are shown in S1 Table.
Survival post treatment
Survival post was assessed in 85 of the 136 patients (Table 2) with some information after the
initial LFT. In univariate analysis the age categories 25–35 years and>35 years were associated
with a greater hazard of death, while the hazard was lower in those treated for>12 months be-
fore LFT, Table 3. In multivariate analysis the association only remained significant for those
aged>35 years, Table 3. Sensitivity analysis including the resistance pattern variable in multi-
variate analysis showed an increased hazard of death for the age categories 25–35 years and
>35 years, with a lower hazard among those with no second line resistance, Table 3. Overall
two year survival post treatment was 62%, and was 45% for those>35 years (p = 0.01), Fig. 3.
Two-year survival in those with>12 months of treatment was 92%. Two-year survival for pa-
tients with less than 6 months of treatment was 52%; significantly lower than for those with
>12 months of treatment (p = 0.04).
Discussion
A high proportion of patients initiating treatment in the Khayelitsha community based DR-TB
program were LFT. LFT occurred early and persisted throughout the treatment period. Being
male and of younger age (15–25 years) were significantly associated with LFT. Overall survival
Fig 2. Post treatment outcomes of the patients lost from DR-TB treatment (January 2009-July 2013).
doi:10.1371/journal.pone.0118919.g002
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among these patients was relatively poor, but still above that reported for untreated DR-TB pa-
tients [19]. Survival was lower again among patients older than 35 years, but there was a trend
for improved survival among patients with a longer duration of treatment. Survival two years
post LFT was 92% among the small group of patients who had receiving at least 12 months
of treatment.
The proportion of patients LFT in this setting is higher than pooled estimates reported in
published systematic reviews and meta-analyses, including one study that only analysed
Table 3. Survival post treatment: Factors associated with time to mortality post treatment.
Variable Univariate analysis Multivariate analysis n = 66 Multivariate analysis+ n = 62
(n)
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Length of treatment (months) (n = 82)
0–3 ref
3–6 0.61 (0.25–1.55) 0.30 0.91 (0.32–2.62) 0.87 0.83 (0.23–2.97) 0.78
6–12 0.64 (0.28–1.49) 0.30 0.97 (0.28–3.32) 0.95 0.81 (0.18–3.68) 0.79
12+ 0.11 (0.10–0.77) 0.03# 0.21 (0.02–1.97) 0.17 0.16 (0.01–1.78) 0.14
Age (years( (n = 82)
0–25 ref
>25–35 3.27 (1.07–9.93) # 0.04# 3.09 (0.96–9.90) 0.06 3.49 (1.06–11.47) # 0.04#
>35 5.08 (1.63–15.79) # 0.01# 3.74 (1.13–12.37) # 0.03# 3.93 (1.04–14.94) # 0.04#
HIV positive (n = 79)
0.95 (0.45–2.0) 0.89
Gender: Male (n = 82)
1.47 (0.69–3.15) 0.32
Converted at LFT** (n = 66)
0.45 (0.21–1.00) 0.05 0.58 (0.20–1.72) 0.33 0.52 (0.14–1.94) 0.33
Resistance pattern (n = 74)
Rifampicin mono resistance ref Ref
MDR no 2ndline resistance 0.50 (0.23–1.09) 0.08 0.35 (0.12–0.97) # 0.04#
MDR plus 2ndline resistance 1.11 (0.31–3.97) 0.88 1.20 (0.21–6.93) 0.84
#statistically signiﬁcant
+Sensitivity analysis-Multivariate analysis including Resistance pattern
**LFT Lost from treatment
doi:10.1371/journal.pone.0118919.t003
Fig 3. Survival post treatment: Overall, Duration of treatment before LFT, and Age at DR-TB diagnosis.
doi:10.1371/journal.pone.0118919.g003
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outcomes from community based DR-TB programs [11, 20, 21]. Our findings are however
comparable to those from Mumbai India (26%), but differ from findings in other settings with-
in South Africa, in Europe and parts of Asia [22–28]. Between 2000 and 2004, the default (LFT
in our study) rate in HIV infected and uninfected patients in 8 provinces across South Africa
was approximately 21%, equivalent to that found in a high HIV setting in KwaZulu Natal be-
tween 2000 and 2003 [23, 24]. However in an analysis of treatment outcomes in the West
Coast/Winelands district for the period 1992 to 2002, the default proportion peaked at 40% in
1997 [22]. In Uzbekistan, Latvia, and New Delhi reported rates have been below 20% [26–28].
It should be noted that in many of these settings treatment is centralized, or where decentral-
ized, this is limited, thus only a low proportion of diagnosed patients start treatment [3, 4], in
contrast to our setting where over the period 2008–2011, 86% of all patients diagnosed with
DR-TB started treatment [8]. Thus, it is likely that we had many patients who would not have
received treatment in a centralized model of care, who may potentially be more likely to be
LFT. Our sample was also larger than reported in the majority of community based programs
reporting lower levels of LFT [6]. Nonetheless, we have previously shown that treatment suc-
cess in our setting is comparable to that in other high HIV settings [8].
Our findings highlight the difficulty of patient retention on long DR-TB treatment regimens
even in a relatively well resourced program. A systematic review by Toczek et al showed that
engagement of community health workers (CHWs) as Directly Observed Therapy (DOT) pro-
viders, provision of DOT throughout the treatment period, patient education and smaller co-
hort sizes (<100 patients), are associated with lower default rates [20]. In the Khayelitsha
program patients receive extensive education, long term support and DOT is provided
throughout the treatment period at the local clinic by nursing staff:- and yet LFT was high sug-
gesting that other factors could be driving LFT.
Males and young age were associated with a greater hazard of LFT, consistent with pub-
lished literature. This could be associated with high risk taking behavior in young males [29].
Males also access health services less frequently than females and adolescents included in this
age category have shown poor adherence to chronic medication, both possible explanations for
our findings [30, 31]. Khayelitsha experiences in-migration from rural areas and internal mi-
gration within the township. Males and young people migrate for school and employment op-
portunities [32] and may out-migrate if these opportunities do not arise, when employment
ends, or to receive care from family during illness. Current patient support and counseling ap-
proaches may therefore not be effective in this population group. Research into strategies tar-
geting this population group is therefore needed. Khayelitsha is also a poor township with high
rates of unemployment and high alcohol and substance abuse [13, 33], which have both been
associated with LFT [34], and require support beyond TB programs.
Absence of culture conversion during the intensive phase and severity of resistance patterns
(pre-XDR-TB and XDR-TB) which have been associated with a lower risk of LFT [26, 35] in
centralized models of care did not show statistically significant associations in our analysis.
However early culture conversion (conversion at four months of treatment), showed a high
hazard ratio (HR 2.14, p = 0.07), which although not reaching statistical significance, suggests
that it could be associated with LFT in our population. Potentially, patients stop treatment
when they start to improve clinically, given the poor tolerability of DR-TB treatment [15]. In-
deed, drug toxicity and treatment fatigue were probably significant underlying factors for pa-
tients stopping treatment despite extensive counseling and support. Current regimens have
severe side effects, comprise a large amount of tablets, include a painful injectable agent, and
have to be taken for a long period [15]. DR-TB patients in Armenia reported drug side effects
and the long duration of treatment as major factors related to LFT [35]. In India, co-infected
patients described the DR-TB drug side effects as ‘worse than the illness itself’ [36]. A fifth of
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the patients who stopped treatment early subsequently returned to treatment. This may have
been prompted by clinical deterioration, or “some recovery” from the drug side effects. Howev-
er, we had no data to explore this further in the present analysis.
Overall, more than 60% of patients survived for at least two years after stopping treatment.
These patients had received treatment for a median period of 7 months and most were HIV in-
fected. Given disease progression among untreated active disease, it is possible that many of
those surviving for this duration no longer had active disease and may not have been infectious
[19, 37]. High rates of LFT are often considered as an indicator of poor program performance,
with suggestions that such programs are worse than none at all [38]. This is based on the as-
sumption that LFT is associated with high levels of resistance amplification. Although our sam-
ple was too small for meaningful conclusions in our population in this regard, (See S1 Table), it
should however be noted that the contribution to ongoing transmission from patients who do
not complete treatment is most likely minimal in comparison to transmission from the large
burden of undiagnosed and untreated cases in high burden settings.
Patient LFT is inherent in DR-TB treatment programs given currently recommended
lengthy and arduous treatment regimens [15]. In the Khayelitsha program innovative interven-
tions to reduce patient LFT now include i)piloting patient-managed treatment in the continua-
tion phase with support from CHWs, and ii) early identification and support for patients who
interrupt treatment and may therefore be at risk of LFT later on. Cash incentives which have
improved adherence in patients with drug sensitive TB [39, 40], may also be effective in DR-
TB as suggested by findings from a national cash incentive program for DR-TB patients in Ec-
uador, where introduction of a monthly cash incentive resulted in a 2.8 fold decrease in the one
year default rate [41]. In Khayelitsha, patients are supported in accessing state provided social
grants that patients diagnosed with TB, who are unable to continue working or are unemployed
are eligible to receive. The high LFT in our supportive setting further highlights the need for
less toxic and shorter drug regimens as key to improving patient retention on treatment and
achieving better outcomes [42].
Our analysis had several limitations. Firstly we could only assess risk factors based on rou-
tinely collected data; hence our assessment of risk factors for LFT is limited since we could not
include socio-behavioural and clinical characteristics in our analysis. LFT is likely determined
by a complex interplay between socio-demographic, behavioural, economic, clinical, bacterio-
logical and programmatic factors some of which cannot be easily assessed with routine data.
Post treatment outcomes were determined passively with no active follow up of patients, there-
fore patient status could have been misclassified, particularly among patients not reported to
have died, who were then regarded as LTFU at the end of observation; therefore our observed
62% two-year survival could be falsely inflated.
LFT in this community based DR-TB program while high is comparable to that in a similar
setting in India, and to that in some centralized programs in high HIV and TB burden settings.
Overall two-year survival post LFT was relatively poor. High rates of LFT should not preclude
treatment scale up, since community based treatment is an effective strategy for increasing ac-
cess to treatment. Further research into interventions for supporting patients undergoing DR-
TB treatment even in community based programs, and improved shorter treatment regimens
are urgently needed.
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